Skip to content

Non-Invasive High-Frequency Oscillatory Ventilation vs Conventional Ventilation for Preterm Neonates.

Effectiveness of Non-Invasive High-Frequency Oscillatory Ventilation vs Conventional Ventilation for Preterm Neonates With Respiratory Distress Syndrome Following Nasal CPAP Failure.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07307079
Enrollment
100
Registered
2025-12-29
Start date
2025-06-01
Completion date
2025-11-30
Last updated
2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Brief summary

Given the high burden of respiratory distress syndrome (RDS) and its complications in resource-constrained settings, identifying effective, low-risk interventions is imperative. The study aimed to assess the improvement in oxygenation and ventilation parameters initiating non-invasive high-frequency oscillatory ventilation (nHFOV) or conventional mechanical ventilation (CMV) and to compare the incidence of air leaks, sepsis, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), prolonged hospital stays, and short-term survival rates.

Detailed description

Global neonatal care is moving toward lung-protective ventilation strategies to improve outcomes for preterm neonates. Evaluating the role of nHFOV in low- and middle-income countries (LMICs) like Pakistan not only helps address local healthcare challenges but also contributes to global efforts to optimize neonatal care across diverse settings. To best of my knowledge no such type of study has been conducted in Pakistan. This study is non-invasive and cost effective. The findings of this study could inform policy decisions and resource allocation in NICUs across Pakistan and other middle-income countries (LMICs).

Interventions

Neonates were managed using a high-frequency oscillatory ventilator with a noninvasive nasal interface. Ventilator settings were adjusted to a mean airway pressure (MAP) of 8-12 cmH₂O, a frequency of 10 Hz, an amplitude adjusted to maintain optimal chest vibration, and an FiO₂ titrated to maintain SpO₂ between 90-94%.

Neonates received invasive ventilation through an endotracheal tube. Settings were adjusted to an initial tidal volume of 4-6 mL/kg, positive end-expiratory pressure (PEEP) of 4-6 cmH₂O, a respiratory rate of 30-50 breaths per minute, and FiO₂ titrated to maintain SpO₂ between 90-94%.

Sponsors

Muhammad Aamir Latif
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 28 Days
Healthy volunteers
No

Inclusion criteria

* Neonates of any gender * Gestational age between 26 and 36 weeks * Diagnosed with RDS. * Failed to respond to nCPAP treatment

Exclusion criteria

* Major congenital anomalies like congenital diaphragmatic hernia, dysmorphism and congenital heart diseases * Early onset sepsis at the time of enrollment

Design outcomes

Primary

MeasureTime frameDescription
Improvement in ventilation parameter24 hoursImprovement in ventilation parameter, measured by arterial blood gas analysis of the assigned ventilation modality was noted.

Secondary

MeasureTime frameDescription
Bronchopulmonary dysplasia36 weeks post-menstrual ageBronchopulmonary dysplasia was considered 'yes' if the patient required supplemental oxygen (\>21% FiO₂) for ≥28 days to maintain oxygen saturation between 90-94%.
Sepsis28 daysAt least 1 abnormality in laboratory findings of WBC \<5,000/mm³, I/T ratio \>0.2, and platelets \<100,000/mm³. or CRP elevated (\>10 mg/L), or procalcitonin elevated (\>2 ng/mL). or blood gas analysis metabolic acidosis (pH \<7.25) was taken as 'yes'.
Ventilator-Associated Pneumonia48 hoursClinically, pneumonia was labeled 'yes' as a new or persistent respiratory distress or worsening gas exchange, increased ventilator requirements (e.g., higher FiO₂ or positive end-expiratory pressure \[PEEP\]), signs of infection (fever (\>38°C) or hypothermia (\<36°C), apnea or bradycardia episodes, tachycardia or hypotension).
Duration of respiratory support28 daysTotal days on modality were noted.
Survival Status at Discharge28 daysThe survival status of the patient was noted as 'alive' or 'deceased'.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026